Orphan drug market access and pricing: strategies for success
When it comes to securing market access and drug pricing for orphan drugs, a one size approach won’t work.
Driven by increasing competition and cost pressures, securing market access now requires developers to take an increasingly sophisticated approach when dealing with payers and HTA organisation. By combining disease information, patient input, real world data and innovative low risk contracting with the wider social and health benefits companies can – and must – build robust value propositions to justify pricing.
Orphan Drugs: Pricing and Market Access Strategies is an expert report that reveals the latest thinking on the proven strategic approaches that will deliver market access and pricing success in the increasingly complex and challenging US and EU5 orphan drug sector.
“Evidence of post-marketing patient benefits, payer re-evaluation and commercial reward for the company should be a continuum. It cannot be just a one-shot assessment at the time of marketing authorisation given the significant payer budgets involved.”
David Jakouloff
Head of Global Market Access at Aegerion
“One way to address payer pushback is to assess and demonstrate some benefit enrichment criteria within your patient population – where you are able to provide some sub-group of interest that has the highest unmet need and would benefit the most from the drug both in terms of efficacy as well as economics.”
Usman Iqbal
Senior Medical Affairs, AstraZeneca
“I think where it gets tricky is when you go to other countries and look at the payment system and at the level of challenge for getting coverage for products. It becomes a question mark or a potential obstacle.”
Tom Croce
Head of Global Patient Advocacy at Shire Pharmaceuticals
Need more information? Contact a consultant for an executive summary and sample pages from the report.
Orphan drug market access and pricing: strategies for success
When it comes to securing market access and drug pricing for orphan drugs, a one size approach won’t work.
Driven by increasing competition and cost pressures, securing market access now requires developers to take an increasingly sophisticated approach when dealing with payers and HTA organisation. By combining disease information, patient input, real world data and innovative low risk contracting with the wider social and health benefits companies can – and must – build robust value propositions to justify pricing.
Orphan Drugs: Pricing and Market Access Strategies is an expert report that reveals the latest thinking on the proven strategic approaches that will deliver market access and pricing success in the increasingly complex and challenging US and EU5 orphan drug sector.
“Evidence of post-marketing patient benefits, payer re-evaluation and commercial reward for the company should be a continuum. It cannot be just a one-shot assessment at the time of marketing authorisation given the significant payer budgets involved.”
David Jakouloff
Head of Global Market Access at Aegerion
“One way to address payer pushback is to assess and demonstrate some benefit enrichment criteria within your patient population – where you are able to provide some sub-group of interest that has the highest unmet need and would benefit the most from the drug both in terms of efficacy as well as economics.”
Usman Iqbal
Senior Medical Affairs, AstraZeneca
“I think where it gets tricky is when you go to other countries and look at the payment system and at the level of challenge for getting coverage for products. It becomes a question mark or a potential obstacle.”
Tom Croce
Head of Global Patient Advocacy at Shire Pharmaceuticals
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved